泌尿器科領域における抗コリンエステラーゼ剤Ubretidの使用経験

Abstract

The results of clinical investigation on the new long acting cholinesterase inhibitor "Ubretid" showed that it could be employed for tornicising the bladder and ureteral musculature. Clinical improvements of symptoms and signs including cystometrograms were observed in 7 of 8 patients with mild bladder neck sclerosis, 5 of 8 patients with neurogenic bladder dysfunction and 1 of 4 patients with vesicoureteral reflux. A dose of 5 mg. (one tablet) once a day by mouth seemed to be adequate. Maintenance on 5 mg. every other day may be desirable in chronic cases. No marked by-effects such as intestinal spasms, vomiting, excessive sweating, increased saliva secretion, muscular fasciculation and cholinergic crisis were encountered in this study.